Human adipose dynamics and metabolic health

Annals of the New York Academy of Sciences

Volumn 1281, Issue 1, 2013, Pages 160-177

  Feng, Bin ^a   Zhang, Tracy ^b   Xu, Haiyan ^a  

^a BROWN UNIVERSITY   (United States)

^b Sharon High School   (United States)

Author keywords

BAT; Lipodystrophy; Obesity; WAT

Indexed keywords

ANTIOBESITY AGENT; GLITAZONE DERIVATIVE; INSULIN; IRISIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; PIOGLITAZONE; ROSIGLITAZONE; SR 1644; SR 1664; TROGLITAZONE; UNCLASSIFIED DRUG;

ADIPOCYTE; ADIPOGENESIS; ADIPOSE TISSUE; ARTICLE; BODY MASS; BROWN ADIPOSE TISSUE; CALORIC INTAKE; CELL DEATH; CLINICAL FEATURE; COLD; DRUG TARGETING; FIBROBLAST; FIBROSIS; GENE MUTATION; GENE OVEREXPRESSION; GENETIC DISORDER; HUMAN; HYPOXEMIA; INFLAMMATION; INSULIN SENSITIVITY; LEPTIN DEFICIENCY; LIPODYSTROPHY; LOSS OF FUNCTION MUTATION; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; SEDENTARY LIFESTYLE; TISSUE GROWTH; WHITE ADIPOSE TISSUE;

EID: 84875653241     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/nyas.12009     Document Type: Article

References (201)

1. Cristancho, A.G. & M.A. Lazar. 2011. Forming functional fat: a growing understanding of adipocyte differentiation. Nat. Rev. Mol. Cell Biol. 12: 722-734.
2. Poissonnet, C.M., A.R. Burdi & S.M. Garn. 1984. The chronology of adipose tissue appearance and distribution in the human fetus. Early Hum. Dev. 10: 1-11.
3. Gesta, S., Y.H. Tseng & C.R. Kahn. 2007. Developmental origin of fat: tracking obesity to its source. Cell 131: 242-256.
4. Billon, N. et al. 2007. The generation of adipocytes by the neural crest. Development 134: 2283-2292.
5. Ailhaud, G., P. Grimaldi & R. Negrel. 1992. Cellular and molecular aspects of adipose tissue development. Annu. Rev. Nutr. 12: 207-233.
6. Rosen, E.D. & O.A. MacDougald. 2006. Adipocyte differentiation from the inside out. Nat. Rev. Mol. Cell Biol. 7: 885-896.
7. Symonds, M.E. et al. 2003. Endocrine and nutritional regulation of fetal adipose tissue development. J. Endocrinol. 179: 293-299.
8. Ibanez, L. et al. 2006. Early development of adiposity and insulin resistance after catch-up weight gain in small-for-gestational-age children. J. Clin. Endocrinol. Metab. 91: 2153-2158.
9. Jaquet, D. et al. 2000. Insulin resistance early in adulthood in subjects born with intrauterine growth retardation. J. Clin. Endocrinol. Metab. 85: 1401-1406.
10. Rigamonti, A. et al. 2011. Rapid cellular turnover in adipose tissue. PLoS One 6: e17637.
11. Spalding, K.L. et al. 2008. Dynamics of fat cell turnover in humans. Nature 453: 783-787.
12. Rosen, E.D. & B.M. Spiegelman. 2000. Molecular regulation of adipogenesis. Annu. Rev. Cell Dev. Biol. 16: 145-171.
13. Tang, W. et al. 2008. White fat progenitor cells reside in the adipose vasculature. Science 322: 583-586.
14. Rodeheffer, M.S., K. Birsoy & J.M. Friedman. 2008. Identification of white adipocyte progenitor cells in vivo. Cell 135: 240-249.
15. Huang, H. et al. 2009. BMP signaling pathway is required for commitment of C3H10T1/2 pluripotent stem cells to the adipocyte lineage. Proc. Natl. Acad. Sci. USA 106: 12670-12675.
16. Tang, Q.Q. & M.D. Lane. 2012. Adipogenesis: from stem cell to adipocyte. Annu. Rev. Biochem. 81: 715-736.
17. Tontonoz, P., E. Hu & B.M. Spiegelman. 1994. Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. Cell 79: 1147-1156.
18. Rosen, E.D. et al. 1999. PPAR gamma is required for the differentiation of adipose tissue in vivo and in vitro. Mol. Cell. 4: 611-617.
19. Tanaka, T. et al. 1997. Defective adipocyte differentiation in mice lacking the C/EBPbeta and/or C/EBPdelta gene. EMBO J. 16: 7432-7443.
20. Mori, T. et al. 2005. Role of Kruppel-like factor 15 (KLF15) in transcriptional regulation of adipogenesis. J. Biol. Chem. 280: 12867-12875.
21. Linhart, H.G. et al. 2001. C/EBPalpha is required for differentiation of white, but not brown, adipose tissue. Proc. Natl. Acad. Sci. USA 98: 12532-12537.
22. Zhang, J.W. et al. 2004. Role of CREB in transcriptional regulation of CCAAT/enhancer-binding protein beta gene during adipogenesis. J. Biol. Chem. 279: 4471-4478.
23. Chen, Z. et al. 2005. Krox20 stimulates adipogenesis via C/EBPbeta-dependent and -independent mechanisms. Cell Metab. 1: 93-106.
24. Birsoy, K., Z. Chen & J. Friedman. 2008. Transcriptional regulation of adipogenesis by KLF4. Cell Metab. 7: 339-347.
25. Oishi, Y. et al. 2005. Kruppel-like transcription factor KLF5 is a key regulator of adipocyte differentiation. Cell Metab. 1: 27-39.
26. Sue, N. et al. 2008. Targeted disruption of the basic Kruppel-like factor gene (Klf3) reveals a role in adipogenesis. Mol. Cell Biol. 28: 3967-3978.
27. Tontonoz, P. & B.M. Spiegelman. 2008. Fat and beyond: the diverse biology of PPARgamma. Annu. Rev. Biochem. 77: 289-312.
28. Tong, Q. et al. 2000. Function of GATA transcription factors in preadipocyte-adipocyte transition. Science 290: 134-138.
29. Ross, S.E. et al. 2000. Inhibition of adipogenesis by Wnt signaling. Science 289: 950-953.
30. James, A.W. et al. 2010. Sonic Hedgehog influences the balance of osteogenesis and adipogenesis in mouse adipose-derived stromal cells. Tissue Eng. Part A. 16: 2605-2616.
31. Wu, J. et al. 2005. The KLF2 transcription factor does not affect the formation of preadipocytes but inhibits their differentiation into adipocytes. Biochemistry 44: 11098-11105.
32. Romao, J.M. et al. 2011. MicroRNA regulation in mammalian adipogenesis. Exp. Biol. Med. 236: 997-1004.
33. Ahima, R.S. & J.S. Flier. 2000. Leptin. Annu. Rev. Physiol. 62: 413-437.
34. Shetty, S., C.M. Kusminski & P.E. Scherer. 2009. Adiponectin in health and disease: evaluation of adiponectin-targeted drug development strategies. Trends Pharmacol. Sci. 30: 234-239.
35. Tchkonia, T. et al. 2002. Fat depot origin affects adipogenesis in primary cultured and cloned human preadipocytes. Am. J. Physiol. Regul. Integr. Comp. Physiol. 282: R1286-R1296.
36. Tchkonia, T. et al. 2006. Fat depot-specific characteristics are retained in strains derived from single human preadipocytes. Diabetes 55: 2571-2578.
37. Wajchenberg, B.L. 2000. Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr. Rev. 21: 697-738.
38. Bahceci, M. et al. 2007. The correlation between adiposity and adiponectin, tumor necrosis factor alpha, interleukin-6 and high sensitivity C-reactive protein levels. Is adipocyte size associated with inflammation in adults J. Endocrinol. Invest. 30: 210-214.
39. Cannon, B. & J. Nedergaard. 2004. Brown adipose tissue: function and physiological significance. Physiol. Rev. 84: 277-359.
40. Sell, H., Y. Deshaies & D. Richard. 2004. The brown adipocyte: update on its metabolic role. Int. J. Biochem. Cell Biol. 36: 2098-2104.
41. Farmer, S.R. 2008. Molecular determinants of brown adipocyte formation and function. Genes Dev. 22: 1269-1275.
42. Bargmann, W., G. von Hehn & E. Lindner. 1968. On the cells of the brown fatty tissue and their innervation. Z. Zellforsch Mikrosk Anat. 85: 601-613.
43. Merklin, R.J. 1974. Growth and distribution of human fetal brown fat. Anat. Rec. 178: 637-645.
44. Carter, B.W. & W.G. Schucany. 2008. Brown adipose tissue in a newborn. Proc. Bayl. Univ. Med. Cent. 21: 328-330.
45. Virtanen, K.A. et al. 2009. Functional brown adipose tissue in healthy adults. N. Engl. J. Med. 360: 1518-1525.
46. Cypess, A.M. et al. 2009. Identification and importance of brown adipose tissue in adult humans. N. Engl. J. Med. 360: 1509-1517.
47. van Marken Lichtenbelt, W.D. et al. 2009. Cold-activated brown adipose tissue in healthy men. N. Engl. J. Med. 360: 1500-1508.
48. Cypess, A.M. et al. 2012. Cold but not sympathomimetics activates human brown adipose tissue in vivo. Proc. Natl. Acad. Sci. USA 109: 10001-10005.
49. Enerback, S. 2010. Brown adipose tissue in humans. Int. J. Obes. 34(Suppl 1): S43-S46.
50. Nedergaard, J., T. Bengtsson & B. Cannon. 2007. Unexpected evidence for active brown adipose tissue in adult humans. Am. J. Physiol. Endocrinol. Metab. 293: E444-E452.
51. Heaton, J.M. 1972. The distribution of brown adipose tissue in the human. J. Anat. 112: 35-39.
52. Nedergaard, J. & B. Cannon. 2010. The changed metabolic world with human brown adipose tissue: therapeutic visions. Cell Metab. 11: 268-272.
53. Ouellet, V. et al. 2012. Brown adipose tissue oxidative metabolism contributes to energy expenditure during acute cold exposure in humans. J. Clin. Invest. 122: 545-552.
54. Orava, J. et al. 2011. Different metabolic responses of human brown adipose tissue to activation by cold and insulin. Cell Metab. 14: 272-279.
55. Ricquier, D., M. Nechad & G. Mory. 1982. Ultrastructural and biochemical characterization of human brown adipose tissue in pheochromocytoma. J. Clin. Endocrinol. Metab. 54: 803-807.
56. Fukuchi, K. et al. 2004. Radionuclide imaging metabolic activity of brown adipose tissue in a patient with pheochromocytoma. Exp. Clin. Endocrinol. Diabetes. 112: 601-603.
57. Wang, Q. et al. 2011. Brown adipose tissue in humans is activated by elevated plasma catecholamines levels and is inversely related to central obesity. PLoS One 6: e21006.
58. Huttunen, P., J. Hirvonen & V. Kinnula. 1981. The occurrence of brown adipose tissue in outdoor workers. Eur. J. Appl. Physiol. Occup. Physiol. 46: 339-345.
59. Kuji, I. et al. 2008. Brown adipose tissue demonstrating intense FDG uptake in a patient with mediastinal pheochromocytoma. Ann. Nucl. Med. 22: 231-235.
60. Wu, J. et al. 2012. Beige adipocytes are a distinct type of thermogenic fat cell in mouse and human. Cell 150: 366-376.
61. Tseng, Y.H. et al. 2008. New role of bone morphogenetic protein 7 in brown adipogenesis and energy expenditure. Nature 454: 1000-1004.
62. Frontini, A. & S. Cinti. 2010. Distribution and development of brown adipocytes in the murine and human adipose organ. Cell Metab. 11: 253-256.
63. Seale, P. et al. 2007. Transcriptional control of brown fat determination by PRDM16. Cell Metab. 6: 38-54.
64. Uldry, M. et al. 2006. Complementary action of the PGC-1 coactivators in mitochondrial biogenesis and brown fat differentiation. Cell Metab. 3: 333-341.
65. Leone, T.C. et al. 2005. PGC-1alpha deficiency causes multi-system energy metabolic derangements: muscle dysfunction, abnormal weight control and hepatic steatosis. PLoS Biol. 3: e101.
66. Lin, J. et al. 2004. Defects in adaptive energy metabolism with CNS-linked hyperactivity in PGC-1alpha null mice. Cell 119: 121-135.
67. Bostrom, P. et al. 2012. A PGC1-alpha-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature 481: 463-468.
68. Leonardsson, G. et al. 2004. Nuclear receptor corepressor RIP140 regulates fat accumulation. Proc. Natl. Acad. Sci. USA 101: 8437-8442.
69. Kang, S. et al. 2005. Effects of Wnt signaling on brown adipocyte differentiation and metabolism mediated by PGC-1alpha. Mol. Cell. Biol. 25: 1272-1282.
70. Scime, A. et al. 2005. Rb and p107 regulate preadipocyte differentiation into white versus brown fat through repression of PGC-1alpha. Cell Metab. 2: 283-295.
71. Montague, C.T. et al. 1997. Congenital leptin deficiency is associated with severe early-onset obesity in humans. Nature 387: 903-908.
72. Gibson, W.T. et al. 2004. Congenital leptin deficiency due to homozygosity for the Delta133G mutation: report of another case and evaluation of response to four years of leptin therapy. J. Clin. Endocrinol. Metab. 89: 4821-4826.
73. Strobel, A. et al. 1998. A leptin missense mutation associated with hypogonadism and morbid obesity. Nat. Genet. 18: 213-215.
74. Farooqi, I.S. et al. 1999. Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N. Engl. J. Med. 341: 879-884.
75. Farooqi, I.S. et al. 2007. Clinical and molecular genetic spectrum of congenital deficiency of the leptin receptor. N. Engl. J. Med. 356: 237-247.
76. Clement, K. et al. 1998. A mutation in the human leptin receptor gene causes obesity and pituitary dysfunction. Nature 392: 398-401.
77. Farooqi, I.S. et al. 2000. Dominant and recessive inheritance of morbid obesity associated with melanocortin 4 receptor deficiency. J. Clin. Invest. 106: 271-279.
78. Lubrano-Berthelier, C. et al. 2006. Melanocortin 4 receptor mutations in a large cohort of severely obese adults: prevalence, functional classification, genotype-phenotype relationship, and lack of association with binge eating. J. Clin. Endocrinol. Metab. 91: 1811-1818.
79. Krude, H. et al. 1998. Severe early-onset obesity, adrenal insufficiency and red hair pigmentation caused by POMC mutations in humans. Nat. Genet. 19: 155-157.
80. Jackson, R.S. et al. 1997. Obesity and impaired prohormone processing associated with mutations in the human prohormone convertase 1 gene. Nat. Genet. 16: 303-306.
81. Farooqi, I.S. et al. 2007. Hyperphagia and early-onset obesity due to a novel homozygous missense mutation in prohormone convertase 1/3. J. Clin. Endocrinol. Metab. 92: 3369-3373.
82. Yeo, G.S. et al. 2004. A de novo mutation affecting human TrkB associated with severe obesity and developmental delay. Nat. Neurosci. 7: 1187-1189.
83. Gray, J. et al. 2006. Hyperphagia, severe obesity, impaired cognitive function, and hyperactivity associated with functional loss of one copy of the brain-derived neurotrophic factor (BDNF) gene. Diabetes 55: 3366-3371.
84. Han, J.C. et al. 2008. Brain-derived neurotrophic factor and obesity in the WAGR syndrome. N. Engl. J. Med. 359: 918-927.
85. Hung, C.C. et al. 2007. Studies of the SIM1 gene in relation to human obesity and obesity-related traits. Int. J. Obes. 31: 429-434.
86. Tobin, J.L. & P.L. Beales. 2007. Bardet-Biedl syndrome: beyond the cilium. Pediatr. Nephrol. 22: 926-936.
87. Ansley, S.J. et al. 2003. Basal body dysfunction is a likely cause of pleiotropic Bardet-Biedl syndrome. Nature 425: 628-633.
88. Sahoo, T. et al. 2008. Prader-Willi phenotype caused by paternal deficiency for the HBII-85 C/D box small nucleolar RNA cluster. Nat. Genet. 40: 719-721.
89. de Smith, A.J. et al. 2009. A deletion of the HBII-85 class of small nucleolar RNAs (snoRNAs) is associated with hyperphagia, obesity and hypogonadism. Hum. Mol. Genet. 18: 3257-3265.
90. Bochukova, E.G. et al. 2010. Large, rare chromosomal deletions associated with severe early-onset obesity. Nature 463: 666-670.
91. Padoan, A. et al. 2004. Differences in fat and lean mass proportions in normal and growth-restricted fetuses. Am. J. Obstet. Gynecol. 191: 1459-1464.
92. Mazziotti, G., C. Gazzaruso & A. Giustina. 2011. Diabetes in Cushing syndrome: basic and clinical aspects. Trends Endocrinol. Metab. 22: 499-506.
93. Chanson, P. & S. Salenave. 2010. Metabolic syndrome in Cushing's syndrome. Neuroendocrinology 92(Suppl 1): 96-101.
94. Kola, B. et al. 2008. Changes in adenosine 5'-monophosphate-activated protein kinase as a mechanism of visceral obesity in Cushing's syndrome. J. Clin. Endocrinol. Metab. 93: 4969-4973.
95. Hotamisligil, G.S. 2006. Inflammation and metabolic disorders. Nature 444: 860-867.
96. Shoelson, S.E., J. Lee & A.B. Goldfine. 2006. Inflammation and insulin resistance. J. Clin. Invest. 116: 1793-1801.
97. Hotamisligil, G.S. & B.M. Spiegelman. 1994. Tumor necrosis factor alpha: a key component of the obesity-diabetes link. Diabetes 43: 1271-1278.
98. Amrani, A. et al. 1996. Interleukin-1 effect on glycemia in the non-obese diabetic mouse at the pre-diabetic stage. J. Endocrinol. 148: 139-148.
99. Sartipy, P. & D.J. Loskutoff. 2003. Monocyte chemoattractant protein 1 in obesity and insulin resistance. Proc. Natl. Acad. Sci. USA 100: 7265-7270.
100. Rotter, V., I. Nagaev & U. Smith. 2003. Interleukin-6 (IL-6) induces insulin resistance in 3T3-L1 adipocytes and is, like IL-8 and tumor necrosis factor-alpha, overexpressed in human fat cells from insulin-resistant subjects. J. Biol. Chem. 278: 45777-45784.
101. Schipper, H.S. et al. 2012. Adipose tissue-resident immune cells: key players in immunometabolism. Trends Endocrinol. Metab. 23: 407-415.
102. Xu, H. et al. 2003. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J. Clin. Invest. 112: 1821-1830.
103. Jiao, P. et al. 2009. Obesity-related upregulation of monocyte chemotactic factors in adipocytes: involvement of nuclear factor-kappaB and c-Jun NH2-terminal kinase pathways. Diabetes 58: 104-115.
104. Nomiyama, T. et al. 2007. Osteopontin mediates obesity-induced adipose tissue macrophage infiltration and insulin resistance in mice. J. Clin. Invest. 117: 2877-2888.
105. Weisberg, S.P. et al. 2006. CCR2 modulates inflammatory and metabolic effects of high-fat feeding. J. Clin. Invest. 116: 115-124.
106. Nara, N. et al. 2007. Disruption of CXC motif chemokine ligand-14 in mice ameliorates obesity-induced insulin resistance. J. Biol. Chem. 282: 30794-30803.
107. Feng, B. et al. 2011. Clodronate liposomes improve metabolic profile and reduce visceral adipose macrophage content in diet-induced obese mice. PLoS One 6: e24358.
108. Patsouris, D. et al. 2008. Ablation of CD11c-positive cells normalizes insulin sensitivity in obese insulin resistant animals. Cell Metab. 8: 301-309.
109. Clement, K. et al. 2004. Weight loss regulates inflammation-related genes in white adipose tissue of obese subjects. FASEB J. 18: 1657-1669.
110. Cancello, R. et al. 2005. Reduction of macrophage infiltration and chemoattractant gene expression changes in white adipose tissue of morbidly obese subjects after surgery-induced weight loss. Diabetes 54: 2277-2286.
111. Cote, M. et al. 2005. Adiponectinemia in visceral obesity: impact on glucose tolerance and plasma lipoprotein and lipid levels in men. J. Clin. Endocrinol. Metab. 90: 1434-1439.
112. Sun, K., C.M. Kusminski & P.E. Scherer. 2011. Adipose tissue remodeling and obesity. J. Clin. Invest. 121: 2094-2101.
113. Pasarica, M. et al. 2009. Reduced adipose tissue oxygenation in human obesity: evidence for rarefaction, macrophage chemotaxis, and inflammation without an angiogenic response. Diabetes 58: 718-725.
114. Ye, J. 2009. Emerging role of adipose tissue hypoxia in obesity and insulin resistance. Int. J. Obes. 33: 54-66.
115. Cinti, S. et al. 2005. Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans. J. Lipid Res. 46: 2347-2355.
116. Divoux, A. et al. 2010. Fibrosis in human adipose tissue: composition, distribution, and link with lipid metabolism and fat mass loss. Diabetes 59: 2817-2825.
117. Khan, T. et al. 2009. Metabolic dysregulation and adipose tissue fibrosis: role of collagen VI. Mol. Cell Biol. 29: 1575-1591.
118. Shaw, A.J., K.A. McLean & B.A. Evans. 1998. Disorders of fat distribution in HIV infection. Int. J. STD AIDS. 9: 595-599.
119. Giralt, M., P. Domingo & F. Villarroya. 2011. Adipose tissue biology and HIV-infection. Best Pract. Res. Clin. Endocrinol. Metab. 25: 487-499.
120. Giralt, M. et al. 2006. HIV-1 infection alters gene expression in adipose tissue, which contributes to HIV- 1/HAART-associated lipodystrophy. Antivir. Ther. 11: 729-740.
121. Bastard, J.P. et al. 2002. Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance. Lancet 359: 1026-1031.
122. Jan, V. et al. 2004. Altered fat differentiation and adipocytokine expression are inter-related and linked to morphological changes and insulin resistance in HIV-1-infected lipodystrophic patients. Antivir. Ther. 9: 555-564.
123. Grinspoon, S. & A. Carr. 2005. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N. Engl. J. Med. 352: 48-62.
124. Carr, A. & D.A. Cooper. 2000. Adverse effects of antiretroviral therapy. Lancet 356: 1423-1430.
125. Misra, A. & A. Garg. 2003. Clinical features and metabolic derangements in acquired generalized lipodystrophy: case reports and review of the literature. Medicine 82: 129-146.
126. Garg, A. 2011. Clinical review: Lipodystrophies: genetic and acquired body fat disorders. J. Clin. Endocrinol. Metab. 96: 3313-3325.
127. Berardinelli, W. 1954. An undiagnosed endocrinometabolic syndrome: report of 2 cases. J. Clin. Endocrinol. Metab. 14: 193-204.
128. Seip, M. 1959. Lipodystrophy and gigantism with associated endocrine manifestations. A new diencephalic syndrome Acta Paediatr. 48: 555-574.
129. Agarwal, A.K. et al. 2002. AGPAT2 is mutated in congenital generalized lipodystrophy linked to chromosome 9q34. Nat. Genet. 31: 21-23.
130. Magre, J. et al. 2001. Identification of the gene altered in Berardinelli-Seip congenital lipodystrophy on chromosome 11q13. Nat. Genet. 28: 365-370.
131. Kim, C.A. et al. 2008. Association of a homozygous nonsense caveolin-1 mutation with Berardinelli-Seip congenital lipodystrophy. J. Clin. Endocrinol. Metab. 93: 1129-1134.
132. Hayashi, Y.K. et al. 2009. Human PTRF mutations cause secondary deficiency of caveolins resulting in muscular dystrophy with generalized lipodystrophy. J. Clin. Invest. 119: 2623-2633.
133. Takeuchi, K. & K. Reue. 2009. Biochemistry, physiology, and genetics of GPAT, AGPAT, and lipin enzymes in triglyceride synthesis. Am. J. Physiol. Endocrinol. Metab. 296: E1195-E1209.
134. Szymanski, K.M. et al. 2007. The lipodystrophy protein seipin is found at endoplasmic reticulum lipid droplet junctions and is important for droplet morphology. Proc. Natl. Acad. Sci. USA 104: 20890-20895.
135. Payne, V.A. et al. 2008. The human lipodystrophy gene BSCL2/seipin may be essential for normal adipocyte differentiation. Diabetes 57: 2055-2060.
136. Shastry, S. et al. 2010. Congenital generalized lipodystrophy, type 4 (CGL4) associated with myopathy due to novel PTRF mutations. Am. J. Med. Genet A. 152A: 2245-2253.
137. Simha, V. et al. 2008. Novel subtype of congenital generalized lipodystrophy associated with muscular weakness and cervical spine instability. Am. J. Med. Genet A. 146A: 2318-2326.
138. Shackleton, S. et al. 2000. LMNA, encoding lamin A/C, is mutated in partial lipodystrophy. Nat. Genet. 24: 153-156.
139. Semple, R.K., V.K. Chatterjee & S. O'Rahilly. 2006. PPAR gamma and human metabolic disease. J. Clin. Invest. 116: 581-589.
140. George, S. et al. 2004. A family with severe insulin resistance and diabetes due to a mutation in AKT2. Science 304: 1325-1328.
141. Rubio-Cabezas, O. et al. 2009. Partial lipodystrophy and insulin resistant diabetes in a patient with a homozygous nonsense mutation in CIDEC. EMBO Mol. Med. 1: 280-287.
142. Cao, H. & R.A. Hegele. 2000. Nuclear lamin A/C R482Q mutation in canadian kindreds with Dunnigan-type familial partial lipodystrophy. Hum. Mol. Genet. 9: 109-112.
143. Okumura, T. 2011. Role of lipid droplet proteins in liver steatosis. J. Physiol. Biochem. 67: 629-636.
144. Xu, L., L. Zhou & P. Li. 2012. CIDE proteins and lipid metabolism. Arterioscler Thromb. Vasc. Biol. 32: 1094-1098.
145. Salam, G.A. 2002. Lipoma excision. Am. Fam. Physician 65: 901-904.
146. Buisson, P. et al. 2006. Cutaneous lipoma in children: 5 cases with Bannayan-Riley-Ruvalcaba syndrome. J. Pediatr. Surg. 41: 1601-1603.
147. Arlotta, P. et al. 2000. Transgenic mice expressing a truncated form of the high mobility group I-C protein develop adiposity and an abnormally high prevalence of lipomas. J. Biol. Chem. 275: 14394-1400.
148. Dei Tos, A.P. 2000. Liposarcoma: new entities and evolving concepts. Ann. Diagn. Pathol. 4: 252-266.
149. Brines, O.A. & M.H. Johnson. 1949. Hibernoma, a special fatty tumor; report of a case. Am. J. Pathol. 25: 467-479.
150. Furlong, M.A., J.C. Fanburg-Smith & M. Miettinen. 2001. The morphologic spectrum of hibernoma: a clinicopathologic study of 170 cases. Am. J. Surg. Pathol. 25: 809-814.
151. Honoki, K. et al. 2010. Hibernoma of the axillary region: a rare benign adipocytic tumor. Rare Tumors 2: e7.
152. Lehmann, J.M. et al. 1995. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J. Biol. Chem. 270: 12953-12956.
153. He, W. et al. 2003. Adipose-specific peroxisome proliferator-activated receptor gamma knockout causes insulin resistance in fat and liver but not in muscle. Proc. Natl. Acad. Sci. USA 100: 15712-15717.
154. Barroso, I. et al. 1999. Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension. Nature 402: 880-883.
155. Raskin, P. et al. 2000. Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with type II diabetes. Diabetologia 43: 278-284.
156. Okuno, A. et al. 1998. Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. J. Clin. Invest. 101: 1354-1361.
157. Trujillo, M.E. & P.E. Scherer. 2006. Adipose tissue-derived factors: impact on health and disease. Endocr. Rev. 27: 762-778.
158. Combs, T.P. et al. 2004. A transgenic mouse with a deletion in the collagenous domain of adiponectin displays elevated circulating adiponectin and improved insulin sensitivity. Endocrinology 145: 367-383.
159. Hevener, A.L. et al. 2007. Macrophage PPAR gamma is required for normal skeletal muscle and hepatic insulin sensitivity and full antidiabetic effects of thiazolidinediones. J. Clin. Invest. 117: 1658-1669.
160. Jiang, C., A.T. Ting & B. Seed. 1998. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 391: 82-86.
161. Marx, N., P. Libby & J. Plutzky. 2001. Peroxisome proliferator-activated receptors (PPARs) and their role in the vessel wall: possible mediators of cardiovascular risk J. Cardiovasc. Risk 8: 203-210.
162. Ghanim, H. et al. 2001. Suppression of nuclear factor-kappaB and stimulation of inhibitor kappaB by troglitazone: evidence for an anti-inflammatory effect and a potential antiatherosclerotic effect in the obese. J. Clin. Endocrinol. Metab. 86: 1306-1312.
163. Aljada, A. et al. 2001. Nuclear factor-kappaB suppressive and inhibitor-kappaB stimulatory effects of troglitazone in obese patients with type 2 diabetes: evidence of an antiinflammatory action J. Clin. Endocrinol. Metab. 86: 3250-3256.
164. Mohanty, P. et al. 2004. Evidence for a potent antiinflammatory effect of rosiglitazone. J. Clin. Endocrinol. Metab. 89: 2728-2735.
165. Odegaard, J.I. et al. 2007. Macrophage-specific PPAR-gamma controls alternative activation and improves insulin resistance. Nature 447: 1116-1120.
166. Feuerer, M. et al. 2009. Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters. Nat. Med. 15: 930-939.
167. Cipolletta, D. et al. 2012. PPAR-gamma is a major driver of the accumulation and phenotype of adipose tissue Treg cells. Nature 486: 549-553.
168. Choi, J.H. et al. 2011. Antidiabetic actions of a non-agonist PPARgamma ligand blocking Cdk5-mediated phosphorylation. Nature 477: 477-481.
169. Pirat, C. et al. 2012. Targeting peroxisome proliferator-activated receptors (PPARs): development of modulators. J. Med. Chem. 55: 4027-4061.
170. Dunn, F.L. et al. 2011. Selective modulation of PPARgamma activity can lower plasma glucose without typical thiazolidinedione side-effects in patients with Type 2 diabetes. J. Diabetes Complications 25: 151-158.
171. Penumetcha, M. & N. Santanam. 2012. Nutraceuticals as Ligands of PPARgamma. PPAR Res. 2012: 858352.
172. Fleischman, A. et al. 2008. Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes Care 31: 289-294.
173. Goldfine, A.B. et al. 2010. The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial. Ann. Intern. Med. 152: 346-357.
174. Romeo, G.R., J. Lee & S.E. Shoelson. 2012. Metabolic syndrome, insulin resistance, and roles of inflammation - mechanisms and therapeutic targets. Arterioscler Thromb. Vasc. Biol. 32: 1771-1776.
175. Berchtold, L.A. et al. 2009. IL-1 receptor antagonism and muscle gene expression in patients with type 2 diabetes. Eur. Cytokine Netw. 20: 81-87.
176. Ofei, F. et al. 1996. Effects of an engineered human anti-TNF-alpha antibody (CDP571) on insulin sensitivity and glycemic control in patients with NIDDM. Diabetes 45: 881-885.
177. Paquot, N. et al. 2000. No increased insulin sensitivity after a single intravenous administration of a recombinant human tumor necrosis factor receptor: Fc fusion protein in obese insulin-resistant patients. J. Clin. Endocrinol. Metab. 85: 1316-1319.
178. Rupnick, M.A. et al. 2002. Adipose tissue mass can be regulated through the vasculature. Proc. Natl. Acad. Sci. USA 99: 10730-10735.
179. Oike, Y. & M. Tabata. 2009. Angiopoietin-like proteins-potential therapeutic targets for metabolic syndrome and cardiovascular disease. Circ. J. 73: 2192-2197.
180. Kunduzova, O. et al. 2008. Apelin/APJ signaling system: a potential link between adipose tissue and endothelial angiogenic processes. FASEB J. 22: 4146-4153.
181. Kolonin, M.G. et al. 2004. Reversal of obesity by targeted ablation of adipose tissue. Nat. Med. 10: 625-632.
182. Kim, D.H., S.C. Woods & R.J. Seeley. 2010. Peptide designed to elicit apoptosis in adipose tissue endothelium reduces food intake and body weight. Diabetes 59: 907-915.
183. Cummings, D.E. 2012. Metabolic surgery for type 2 diabetes. Nat. Med. 18: 656-658.
184. Mohammed, B.S. et al. 2008. Long-term effects of large-volume liposuction on metabolic risk factors for coronary heart disease. Obesity 16: 2648-2651.
185. Klein, S. 2010. Is visceral fat responsible for the metabolic abnormalities associated with obesity?: implications of omentectomy. Diabetes Care 33: 1693-1694.
186. Astrup, A. et al. 1997. Fat metabolism in the predisposition to obesity. Ann. N .Y. Acad. Sci. 827: 417-430.
187. Bartlett, J., M. Brunner & K. Gough. 2010. Deliberate poisoning with dinitrophenol (DNP): an unlicensed weight loss pill. Emerg. Med. J. 27: 159-160.
188. Grundlingh, J. et al. 2011. 2, 4-dinitrophenol (DNP): a weight loss agent with significant acute toxicity and risk of death. J. Med. Toxicol. 7: 205-212.
189. Dulloo, A.G. 2011. The search for compounds that stimulate thermogenesis in obesity management: from pharmaceuticals to functional food ingredients. Obes. Rev. 12: 866-883.
190. Snitker, S. et al. 2000. The sympathetic nervous system and obesity: role in aetiology and treatment. Obes. Rev. 1: 5-15.
191. Acheson, K.J. et al. 1980. Caffeine and coffee: their influence on metabolic rate and substrate utilization in normal weight and obese individuals. Am. J. Clin. Nutr. 33: 989-997.
192. Astrup, A. et al. 1985. Enhanced thermogenic responsiveness during chronic ephedrine treatment in man. Am. J. Clin. Nutr. 42: 83-94.
193. Arch, J.R. et al. 1984. Atypical beta-adrenoceptor on brown adipocytes as target for anti-obesity drugs. Nature 309: 163-165.
194. Arch, J.R. 2008. The discovery of drugs for obesity, the metabolic effects of leptin and variable receptor pharmacology: perspectives from beta3-adrenoceptor agonists. Naunyn. Schmiedebergs Arch. Pharmacol. 378: 225-240.
195. Rothwell, N.J. & M.J. Stock. 1983. Diet-induced thermogenesis. Adv. Nutr. Res. 5: 201-220.
196. Tran, T.T. & C.R. Kahn. 2010. Transplantation of adipose tissue and stem cells: role in metabolism and disease. Nat. Rev. Endocrinol. 6: 195-213.
197. Ahfeldt, T. et al. 2012. Programming human pluripotent stem cells into white and brown adipocytes. Nat. Cell Biol. 14: 209-219.
198. Gunawardana, S.C. & D.W. Piston. 2012. Reversal of type 1 diabetes in mice by brown adipose tissue transplant. Diabetes 61: 674-682.
199. Timmons, J.A. et al. 2012. Is irisin a human exercise gene Nature 488: E9-E10; discussion E10-1.
200. Huh, J.Y. et al. 2012. FNDC5 and irisin in humans: I. Predictors of circulating concentrations in serum and plasma and II. mRNA expression and circulating concentrations in response to weight loss and exercise. Metabolism 61: 1725-1736.
201. Hemmeryckx, B., M.F. Hoylaerts & H.R. Lijnen. 2012. Effect of premature aging on murine adipose tissue. Exp. Gerontol. 47: 256-262.